Abstract
Predictive health intelligence company Prescient Medicine, has acquired PGxL Laboratories, a leading reference lab for pharmacogenetics testing. The acquisition expands Prescient’s laboratory capabilities, and allows it to strengthen its working relationships with health insurers, and potentially offering patients better access to their suite of pharmacogenomic tools.
Pharmacogenomic testing provides information on an individual’s ability to process certain drugs based on their genetic makeup. One area of growth for Prescient is its validated genetic test, LifeKit Predict, that assesses an patient’s genetic risk of opioid addiction. LifeKit Predict, along with the company’s other genetic tests, will be processed at the Louisville facility by the end of the year.
“In light of the current opioid crisis, it’s important that, as a company, Prescient continuously finds opportunities to develop, enhance, and refine tools that can better predict and inform patient outcomes,” said Keri Donaldson, M.D., founder and CEO of Prescient Medicine. “The purchase of PGxL is an opportunity to better service the growing list of clinics, doctors, and patients who see the value in important clinical tools like LifeKit Predict. We’re excited about the potential to drive better access to our genetic tools for the patients who need them most.”
Megan Miks / Getty Images
